Close Menu

NEW YORK (GenomeWeb) – Veracyte reported after the close of the market on Monday that its second quarter revenues rose 24 percent year over year as it beat analysts' consensus estimates on both the top and bottom lines.

For the three months ended June 30, the South San Francisco, California-based molecular diagnostics firm reported total revenues of $22.8 million, compared to $18.4 million a year ago. On average, analysts had expected Q2 revenues of $20.6 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
27
Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.